Medicine
Blood Cancer news, research, studies, and rapid health briefings. Visit Viral Vitalism for plain-language context, evidence boundaries, and related signals.
News cycle
Penn Medicine reports decade-long follow-up from one of the earliest CAR-T lymphoma trials, with some patients alive without relapse after a single infusion.
Why now
Long-term follow-up turns early CAR-T enthusiasm into a decade-scale remission signal for some patients.
Tregzi uses donor stem cells plus regulatory and conventional T cells to improve chronic GVHD-free survival after matched-donor stem cell transplant for eligible adult blood-cancer patients.
Why now
FDA approval turns a complex transplant-engineering approach into a patient-access story for blood-cancer survivors facing chronic GVHD risk.
After intensive chemotherapy did not bring complete remission for acute lymphoblastic leukemia, Maureen's own T cells were collected, modified in England, and returned for infusion.
Why now
A fresh hospital patient story makes CAR-T feel like a human process, not just a platform technology.
Research map
Research records connected to this topic through topic tags, source records, and timeline events.
No directly linked studies are available for this page yet. Topic-only matches are not shown as evidence.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No selling your information. Unsubscribe anytime.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
